Nippon Shokubai
VC Fund
Tokyo, Japan
Nippon Shokubai is a VC fund in Tokyo focused on Biotechnology and Pharmaceutical. Since 1941, NIPPON SHOKUBAI has grown up its business with unique catalyst technology.They have supplied, for example, Ethylene oxide, Acrylic acid, automobile catalyst, process catalyst and so on. Among all, their global market share of superabsorbent polymer comes up to No.1, now. NIPPON SHOKUBAI is a global chemical company with its corporatemission as "Providing affluence and comfort to people and society, with their unique technology".
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nippon Shokubai invests in
Stages Nippon Shokubai invests in
Countries Nippon Shokubai invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mark Holzer
|
|||
Investment Focus
Industry
- Biotechnology 2 (100%)
- Pharmaceutical 2 (100%)
- Health Care 1 (50%)
- Manufacturing 1 (50%)
- Clinical Trials 1 (50%)
Stage
- Series A 1 (50%)
- Funding Round 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mark Holzer
Sr. Marketing Manager, Fine Chemicals - Nippon Shokubai America Industries
|
Sr. Marketing Manager, Fine Chemicals - Nippon Shokubai America Industries | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GlyTech
|
GlyTech is focused on the application of glycan production and chemical glycosylation technologies to the development of innovative and improved medicines such as biopharmaceuticals and oligonucleotide therapeutics. | $141.7M / Series A / May 28, 2018 | |
Rena Therapeutics
|
In the pharmaceutical market, attention has been focused on nucleic acid drugs to meet unmet medical needs such as cancer and intractable diseases.This is because nucleic acid drugs have the following advantages.It is possible to target intracellular drug molecules that could not be targeted by conventional drugsDrug discovery research is possiblefor any gene as long as there is technology to deliver nucleic acids to the expression siteMore specific than low molecular weight compounds and less susceptible to side effects Unlike antibody drugs, nucleic acid drugs can be manufactured by chemical synthesis at a relatively low cost. | $85M / Jun 30, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nippon Shokubai invest in?
Nippon Shokubai invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nippon Shokubai?
Public channels for Nippon Shokubai include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nippon Shokubai?
The team at Nippon Shokubai includes Mark Holzer (Sr. Marketing Manager, Fine Chemicals - Nippon Shokubai America Industries). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
